Active Ingredient History
Pegloticase is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not effective or are not tolerated. The drug is administered by infusion intravenously. Since October 2023, Amgen Inc. has been the marketer of pegloticase in the U.S. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Diabetes Complications (Phase 2)
Diabetes Mellitus (Phase 2)
Diabetes Mellitus, Type 2 (Phase 2)
Diabetic Nephropathies (Phase 2)
Gout ()
Hyperuricemia (Phase 2)
Kidney Transplantation (Phase 4)
Lymphoma (Phase 4)
Neoplasms (Phase 4)
Tumor Lysis Syndrome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
